In a bid to bolster its neuroscience portfolio, Janssen has entered into a global license and development agreement with Pipeline Therapeutics for the investigational compound, PIPE-307, to treat nervous system disorders. Through this deal, that could be worth up to US$1.075 B, Janssen will obtain a worldwide license for PIPE-307's research, development, and commercialisation in all potential indications, while Pipeline will retain the right to advance the therapy in relapsing-remitting multiple sclerosis (RRMS) through the conduct of a Phase II clinical trial. The agreement will aid in strengthening both companies' neurological portfolios.